Friday 22nd April 2022
Developing the Next Generation of Medicine
SRUK co-funds a MRC Clinical Research Training Fellowship to advance research into treatments for interstitial lung disease.
Wednesday 20th April 2022
Grant Call: Quality of Life
Ongoing research towards developing new treatments and therapies has a cumulative effect in improving quality of life, but can the problem be addressed directly?
Friday 16th April 2021
A Design for Life: is scleroderma in the genes?
What is the link between our genetic code and developing scleroderma? Researchers from Spain have recently studied genetic alterations and established a connection with the pathways that dictate the clinical features of scleroderma. The study is significant because increasing our understanding of the genetic pathway could be a faster route towards identifying effective new therapies for this complex condition.
Thursday 1st April 2021
Open Research - revolutionising the publishing process for SRUK research
SRUK is working with our partners at the Association of Medical Research Charities via their new Open Research Platform, to revolutionise the publishing process for our researchers. This will enable SRUK-funded research groups to publish their work in a streamlined and cost-effective way, with the ultimate goal of translating new knowledge into effective treatments for people living with scleroderma.
Tuesday 28th April 2020
Approval of nintedanib for systemic sclerosis-associated interstitial lung disease
Nintedanib, a drug that slows the rate of lung fibrosis, has been approved as a treatment for individuals with systemic sclerosis-associated interstitial lung disease, the first option to have been made available.
Thursday 4th April 2019
EZH2: what role does this molecule play in the progression of scleroderma?
Many scientific investigations concerning scleroderma focus on uncovering more about the processes that contribute to a person presenting symptoms. This is because if the driving factors behind it are defined, treatments can be applied to this area to limit the progression of the condition, either by blocking biological mechanisms or by obstructing involved molecules.
Tuesday 25th April 2017
Focus on scleroderma and the heart at BSR annual meeting
Tuesday 25th April 2017
European Scleroderma Observational Study
Thursday 20th April 2017
c-Kit Pathway Influences Scleroderma Development
Thursday 20th April 2017
Nailfold Capillaroscopy as a Research Tool